12.09
21-2月-25 16:45:00
15 分の遅延
株式
-0.08
-0.66%
本日の幅
11.70 - 12.51
ISIN
N/A
ソース
NASDAQ
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
07 2 2025 08:00:00 提供 Nasdaq GlobeNewswire